Stevanato Group Investor Presentation

Reconciliation of Non-GAAP Financial Measures (1/9) Reconciliation of Revenue to Constant Currency Revenue (Amounts in € millions) Three months ended December 31, 2023 Reported Revenue (IFRS GAAP) Effect of changes in currency translation rates Organic Revenue (Non-IFRS GAAP) Biopharmaceutical and Diagnostic Solutions Engineering 260.0 3.8 263.8 60.6 0.1 60.7 Year ended December 31, 2023 Reported Revenue (IFRS GAAP) Effect of changes in currency translation rates Organic Revenue (Non-IFRS GAAP) Biopharmaceutical and Diagnostic Solutions SG, Stevanato Group Stevanato Group Investor Presentation, March 2024 Engineering 879.3 8.2 206.1 0.2 887.5 206.3 38

View entire presentation